Evidence map›Paper›PMID 41392942›Full record

ArticleFuture oncology (London, England)2026

Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial.

Richard M Zuniga, Ari VanderWalde, Lee S Schwartzberg, David R Spigel, Luke Passler, Jason Hong, Michael Howland, Walter C Darbonne, Tania Szado, Davey Daniel

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04632992 (MyTACTIC), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04632992 phase2completednot on this map

MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

TypeinterventionalSponsorGenentech, Inc.Ran2021 to 2024Enrolled252ConditionsAdvanced Unresectable or Metastatic Solid MalignancyArmsEntrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Richard M ZunigaHematology/Oncology, OneOncology, Inc., Nashville, TN, USA.
Ari VanderWaldeClinical Research, West Cancer Center and Research Institute, Germantown, TN, USA.
Lee S SchwartzbergPennington Cancer Institute, Renown Health, Reno, NV, USA.
David R SpigelSarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA.
Luke PasslerGenentech, Inc., South San Francisco, CA, USA.
Jason HongGenentech, Inc., South San Francisco, CA, USA.
Michael HowlandGenentech, Inc., South San Francisco, CA, USA.
Walter C DarbonneGenentech, Inc., South San Francisco, CA, USA.
Tania SzadoGenentech, Inc., South San Francisco, CA, USA.
Davey DanielHematology/Oncology, OneOncology, Inc., Nashville, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsLack of diversity in clinical trial populations often results in healthcare inequity. This retrospective analysis presents the impact of implementing inclusive research practices on the diversity of the MyTACTIC trial population. PATIENTS &

methodsAdult patients with advanced solid tumors were enrolled from large academic centers or community cancer clinics and a number of inclusive research practices were implemented to diversify patient recruitment. We summarized race/ethnicity data of the study population related to the sites' catchment area.

resultsOverall, 252 patients were enrolled (83% White). Community clinics represented 95% of screening sites (enrolled 249/252 patients). The proportion of patients from racial/ethnic minorities was generally higher in study centers from ethnically diverse catchment areas. Streamlining the protocol and implementing a free transport scheme to improve patient recruitment yielded positive feedback from site staff; 14 patients (5.5%) used the transportation service.

conclusionFindings from the MyTACTIC trial suggest that running trials at community oncology sites does not, by itself, increase patient diversity; other efforts are also necessary. NCT04632992.

Indexed as

Biomarkers, TumorClinical Trials, Phase II as TopicNeoplasmsPatient SelectionAdultAgedFemaleHumansMaleMiddle AgedMulticenter Studies as TopicRetrospective StudiesBiomarkers, TumorBiomarkersbiomarkers/oncogenes/molecular oncologyclinical trialsoutcomes researchsolid tumors

Identifiers

PMID41392942
PMCPMC12773618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.